Last updated: July 27, 2026
Ospemifene (Osphena) is an oral selective estrogen receptor modulator (SERM) approved for moderate to severe dyspareunia due to vulvar and vaginal atrophy (VVA) in postmenopausal women. The current commercial profile is dominated by the branded launch in the US and ongoing global uptake driven by payer coverage and guideline alignment. Public clinical-trials activity is concentrated in label-expansion strategies, comparative/real-world effectiveness evidence, and safety/tolerability follow-on studies rather than broad late-stage efficacy programs.
No complete, citation-grade dataset is available in the provided context to quantify: (1) the full current status of all ongoing clinical trials by phase, (2) the latest enrollment and primary endpoint readouts, (3) the latest prescription or revenue time series by geography and channel, or (4) which specific filings/trials are active for 2026–2031. Because this response must be complete and accurate, no market projections or trial status tables can be produced without verifiable sources.
What is ospemifene approved for, and what label limits drive demand?
Ospemifene is approved for treatment of moderate to severe dyspareunia due to vulvar and vaginal atrophy (VVA) in postmenopausal women. Demand is constrained by: (1) diagnostic specificity (VVA-related dyspareunia versus broader GSM symptom clusters), (2) competition from vaginal estrogen, vaginal DHEA, and other nonhormonal options, (3) payer restrictions linked to age, comorbidities, and prior therapy steps, and (4) safety-related prescribing considerations typical for SERMs.
Key commercial demand drivers
- Oral administration differentiates from local therapies, but does not eliminate “local-first” payer logic.
- Uptake depends on gyn-and-menopause specialist prescribing patterns and formulary access.
- Adherence is influenced by tolerability and symptom-response time; persistent switching is common in GSM franchises.
Key commercial demand constraints
- Limited label breadth outside dyspareunia/VVA.
- Patient selection affects persistence and line-of-therapy conversion.
- Safety surveillance expectations for estrogen pathway agents shape formulary behavior.
What clinical trials are ongoing for ospemifene, and what are the latest readouts?
Featured snippet answer: The most actionable way to track “latest readouts” and trial status for ospemifene is via the trial registry record status and posted results in clinical trial databases, then mapping each study to phase, endpoint, and population.
No verifiable, up-to-date trial registry extracts are available in the provided context to enumerate the current trial list, phase distribution, enrollment status, and endpoint outcomes. A complete clinical-trials update cannot be produced to the standards required for investment, licensing, or litigation decisions.
Where trial activity typically clusters for ospemifene (common patterns)
- Label-expansion studies in related manifestations within GSM/VVA
- Comparative effectiveness or real-world evidence collection
- Long-term safety/tolerability follow-on designs
- Pharmacovigilance and risk-management related studies
When does ospemifene lose exclusivity in key markets, and how does that affect forecasting?
Featured snippet answer: Exclusivity timing for ospemifene depends on US patent/Orange Book listings and corresponding regulatory exclusivities across jurisdictions; it then drives generic entry probability and sales erosion curves.
No verified patent and regulatory-exclusivity timeline data is included in the provided context, so a definitive “lose exclusivity” schedule by country and dosage form cannot be stated.
What usually determines exclusivity and erosion timing for SERMs
- Composition-of-matter and formulation patents
- Method-of-use or label-protection patents (dyspareunia/VVA-related claims)
- Regulatory exclusivities and data exclusivity (where applicable)
- Patent challenges (Paragraph IV in the US) and settlement terms
What is the Orange Book status of ospemifene?
Featured snippet answer: Orange Book status requires listing-by-listing inspection of NDA holders, drug product identifiers, and associated patents with expiration dates.
No Orange Book listing data is available in the provided context, so an accurate Orange Book table (listing numbers, patent numbers, claim types, expiration dates, and regulatory exclusivity) cannot be generated.
Which companies are developing generics or biosimilars for ospemifene?
Featured snippet answer: Ospemifene is a small-molecule SERM; the competitive threat is generic development, not biosimilars.
No verified ANDA/authorized generic activity, Paragraph IV filings, or filer identities are available in the provided context. A complete competitive threat register cannot be produced.
How strong is the patent estate for ospemifene, and what patents drive litigation risk?
Featured snippet answer: Patent strength is driven by claim scope, remaining life, and whether claims are directed to active ingredient, formulation, and/or method-of-use.
No patent-number-level estate data is included in the provided context. Without a verified patent map, strength scoring and litigation-risk assessment cannot be provided in a complete, accurate way.
What formulations are protected for ospemifene, and do delivery-system patents matter?
Featured snippet answer: For ospemifene, formulation protection can affect generic readiness if specific excipients, manufacturing processes, or tablet properties are covered.
No formulation patent details are available in the provided context, so a protected formulation landscape cannot be tabulated.
What generic entry risks exist for ospemifene, including Paragraph IV scenarios?
Featured snippet answer: US generic entry risk depends on Orange Book patent coverage, the feasibility of a “carve-out” or design-around, and the probability of an injunction or delayed launch due to litigation/settlement.
No Paragraph IV or settlement documentation is available in the provided context, so risk probabilities and scenario timelines cannot be produced.
What FDA regulatory pathway applies to ospemifene, and what filings would generics use?
Featured snippet answer: As a previously approved branded small molecule, new generic copies typically use ANDA pathways referencing the listed drug.
No FDA regulatory dossier data is included in the provided context to support a listing of reference products, required bioequivalence study characteristics, or risk points around FDA chemistry/manufacturing controls.
Market analysis: How big is the ospemifene opportunity, and which segments buy it?
Featured snippet answer: The addressable market is postmenopausal women with VVA-related dyspareunia, with segment share shaped by oral convenience versus local therapies and payer access.
No current sales/revenue dataset is available in the provided context to quantify:
- US prescription counts and net sales trend
- Market share versus local estrogen/DHEA and nonhormonal competitors
- Geographical split (US versus EU and other regions)
- Channel mix (commercial, specialty distribution, payer categories)
Ospemifene revenue projection: What sales range and CAGR are realistic (2026–2031)?
Featured snippet answer: A credible projection requires validated historical sales, market share trajectory, and modeled generic erosion or competitive shocks. No such underlying dataset is present in the provided context.
A complete projection cannot be generated without:
- Verified historical market size and net sales
- Verified payer/formulary penetration and persistence metrics
- Verified exclusivity and patent timeline
- Verified competitive entry signals and timelines
Key competitive landscape: How does ospemifene compare with vaginal estrogen, DHEA, and nonhormonal therapies?
Featured snippet answer: Ospemifene is an oral systemic SERM option; most competitors are local therapies (vaginal estrogens, vaginal DHEA, and nonhormonal moisturizers/lubricants depending on country and guideline). The comparison is shaped by symptom improvement speed, ease of use, safety perception, and payer coverage.
No competitive-specific clinical or reimbursement outcome datasets are provided in the context to support a quantified comparative positioning.
Comparison dimensions that typically determine share shifts
- Oral versus local administration
- Payer coverage rules for step therapy or prior authorization
- Safety perceptions in women with hormone-sensitive comorbidities
- Time to dyspareunia response and durability
- Formulary preferences for “single-ingredient” versus multi-ingredient products
Key Takeaways
- Ospemifene is approved for moderate to severe dyspareunia due to VVA in postmenopausal women, with demand shaped by label scope, payer access, and competitive pressure from local therapies.
- A complete clinical-trials update and a 2026–2031 market projection require verified trial registry and commercial datasets that are not present in the provided context.
- Patent/Orange Book status and generic-entry risk cannot be stated without listing-level data.
FAQs
- What is the current FDA approval status of ospemifene and are there any label updates?
- What endpoints do ospemifene trials typically use for VVA-related dyspareunia, and how do they map to regulatory expectations?
- How do payer restrictions and step therapy affect ospemifene persistence versus vaginal estrogen or DHEA?
- What is the typical generics risk framework for a small-molecule SERM in the US Orange Book?
- Which real-world evidence metrics most predict switching to or from oral VVA therapies like ospemifene?
References (APA)
- [No citable sources were provided in the prompt for trial status, sales data, exclusivity, or Orange Book listings.]
